Table 2 Summary of patients’ characteristics
Variable | Descriptive statistics | |
|---|---|---|
Age, median (range) years | 50.5 (27–73) | |
Sex, n (%) | Female | 7 (58.3) |
Male | 5 (41.7) | |
Type of vaccine received, n (%) | Moderna mRNA-1273 | 2 (16.7) |
ChAdOx1-S | 1 (8.3) | |
Pfizer-BioNTec | 7 (58.3) | |
CoronaVac | 1 (8.3) | |
Pfizer-BioNTec and CoronaVa | 1 (8.3) | |
Duration from vaccination to symptoms onset, median (range) weeks | 2.5 (0–8) | |
Dose after which symptoms appeared, n (%) | 1st dose | 5 (41.7) |
2nd dose | 6 (50) | |
4th dose | 1 (8.3) | |
Past medical history of autoimmune disease, n (%) | Â | 3 (25) |
Diabetic ketoacidosis at presentation (DKA), n (%) | 5 (41.7) | |